Literature DB >> 9068084

Gadolinium chloride pretreatment protects against hepatic injury but predisposes the lungs to alveolitis after lipopolysaccharide administration.

A P Brown1, J R Harkema, A E Schultze, R A Roth, P E Ganey.   

Abstract

Exposure to lipopolysaccharide (LPS) can result in multi-organ failure and death. After an intravenous injection of LPS into rats, neutrophils (PMN) rapidly accumulate in the liver sinusoids and pulmonary vasculature, and PMN play a critical role in producing both hepatic and pulmonary injury. Kupffer cells (KC), the resident macrophages of the liver, phagocytose LPS and produce inflammatory mediators which may be chemotactic and stimulatory for PMN. The purpose of this study was to determine whether inhibition of KC function affects PMN accumulation and the development of parenchymal injury in the liver and lungs after systemic administration of LPS. Female, Sprague-Dawley rats (180-230 g) were pretreated with either gadolinium chloride-6H2O (GdCl3; 10 mg/kg, intravenously), to inactivate KC, or saline vehicle 24 h before receiving either LPS (4 mg/kg, intravenously) or saline vehicle. Rats were killed 1.5, 6, and 24 h after LPS administration. In a preliminary study, exposure to GdCl3 decreased uptake of carbon in the liver, indicating inhibition of phagocytosis by KC. Ninety minutes after administration of LPS, PMN accumulated in the livers of LPS-treated rats, and this effect was not altered by pretreatment with GdCl3. Similarly, exposure to LPS resulted in PMN accumulation in the pulmonary tissue, which was unaffected by GdCl3 pretreatment. Exposure to GdCl3 before LPS administration resulted in a significant increase in the number of PMN recovered by bronchoalveolar lavage at 24 h, indicating diffuse acute alveolitis. LPS-induced hepatic injury was prevented by pretreatment with GdCl3; however, the increased wet lung/body weight ratio observed after LPS administration was unaffected by GdCl3. These results confirm that inactivation of KC protects against hepatic injury and extend this finding by ruling out inhibition of hepatic PMN accumulation as a mechanism for this effect. The data also suggest that treatment with GdCl3 predisposes the lungs to alveolitis during systemic exposure to LPS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9068084     DOI: 10.1097/00024382-199703000-00006

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  6 in total

Review 1.  Animal models of acute hepatic failure.

Authors:  T M Rahman; H J Hodgson
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

2.  3,3'-Diindolylmethane attenuates LPS-mediated acute liver failure by regulating miRNAs to target IRAK4 and suppress Toll-like receptor signalling.

Authors:  S Tomar; M Nagarkatti; P S Nagarkatti
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

3.  Propofol reduces liver dysfunction caused by tumor necrosis factor-α production in Kupffer cells.

Authors:  Jiazheng Li; Nobuhisa Kandatsu; Guo-Gang Feng; Jia-Zhen Jiang; Lei Huang; Hiroyuki Kinoshita; Shoshiro Okada; Yoshihiro Fujiwara
Journal:  J Anesth       Date:  2016-02-16       Impact factor: 2.078

Review 4.  Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models.

Authors:  Xiaomin Deng; James P Luyendyk; Patricia E Ganey; Robert A Roth
Journal:  Pharmacol Rev       Date:  2009-09       Impact factor: 25.468

5.  Role of pulmonary intravascular macrophages in endotoxin-induced lung inflammation and mortality in a rat model.

Authors:  Sukhjit S Gill; Sarabjeet S Suri; Kyathanahalli S Janardhan; Sarah Caldwell; Tanya Duke; Baljit Singh
Journal:  Respir Res       Date:  2008-10-24

6.  Cystathionine-Gamma-Lyase Gene Deletion Protects Mice against Inflammation and Liver Sieve Injury following Polymicrobial Sepsis.

Authors:  Ravinder Reddy Gaddam; Robin Fraser; Alireza Badiei; Stephen Chambers; Victoria C Cogger; David G Le Couteur; Isao Ishii; Madhav Bhatia
Journal:  PLoS One       Date:  2016-08-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.